Valuation Boston Scientific Corporation
Equities
BSX
US1011371077
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 102.69 USD | -2.18% |
|
+2.67% | +14.97% |
| 11-13 | Worldwide Healthcare improves in first-half; sees lower final dividend | AN |
| 11-06 | Elutia Q3 revenue falls short of estimates, gross margin improves | RE |
Company Valuation: Boston Scientific Corporation
Data adjusted to current consolidation scope
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 51,478 | 60,534 | 66,273 | 84,691 | 131,642 | 152,232 | - | - |
| Change | - | 17.59% | 9.48% | 27.79% | 55.44% | 15.64% | - | - |
| Enterprise Value (EV) 1 | 58,887 | 67,674 | 74,280 | 92,928 | 141,974 | 161,079 | 157,685 | 155,780 |
| Change | - | 14.92% | 9.76% | 25.1% | 52.78% | 13.46% | -2.11% | -1.21% |
| P/E ratio | -300x | 61.6x | 103x | 54x | 71.5x | 49.7x | 40x | 33.5x |
| PBR | 3.32x | 3.64x | 3.77x | 4.39x | 6.05x | 6.17x | 5.38x | 4.69x |
| PEG | - | -0x | -3x | 0x | 4.3x | 0.8x | 1.6x | 1.7x |
| Capitalization / Revenue | 5.19x | 5.09x | 5.23x | 5.95x | 7.86x | 7.58x | 6.8x | 6.17x |
| EV / Revenue | 5.94x | 5.69x | 5.86x | 6.53x | 8.48x | 8.02x | 7.05x | 6.31x |
| EV / EBITDA | 19.4x | 16.5x | 20.8x | 22.6x | 29.3x | 26.2x | 22.7x | 20x |
| EV / EBIT | 30.7x | 22.5x | 22.9x | 24.9x | 31.3x | 28.6x | 24.8x | 21.8x |
| EV / FCF | 52x | 51.4x | 79.2x | 51.9x | 53.7x | 53.3x | 50.6x | 34.9x |
| FCF Yield | 1.92% | 1.94% | 1.26% | 1.93% | 1.86% | 1.88% | 1.98% | 2.86% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.12 | 0.69 | 0.45 | 1.07 | 1.25 | 2.065 | 2.567 | 3.068 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 9,913 | 11,888 | 12,682 | 14,240 | 16,747 | 20,075 | 22,372 | 24,685 |
| EBITDA 1 | 3,040 | 4,103 | 3,574 | 4,106 | 4,839 | 6,150 | 6,941 | 7,804 |
| EBIT 1 | 1,917 | 3,010 | 3,241 | 3,738 | 4,529 | 5,626 | 6,347 | 7,135 |
| Net income 1 | -173 | 985 | 642 | 1,570 | 1,853 | 3,020 | 3,759 | 4,496 |
| Net Debt 1 | 7,409 | 7,140 | 8,007 | 8,237 | 10,332 | 8,847 | 5,453 | 3,548 |
| Reference price 2 | 35.95 | 42.48 | 46.27 | 57.81 | 89.32 | 102.69 | 102.69 | 102.69 |
| Nbr of stocks (in thousands) | 1,431,921 | 1,424,992 | 1,432,311 | 1,464,983 | 1,473,827 | 1,482,442 | - | - |
| Announcement Date | 03/02/21 | 02/02/22 | 01/02/23 | 31/01/24 | 05/02/25 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 50.83x | 8.19x | 26.74x | -.--% | 156B | ||
| 32.51x | 5.55x | 22x | 0.29% | 218B | ||
| 74.43x | 19.63x | 45.81x | -.--% | 200B | ||
| 42.77x | 6.91x | 22.36x | 0.56% | 156B | ||
| 21.64x | 2.58x | 12.7x | 2.43% | 56.08B | ||
| 37.9x | 7.74x | 25.61x | -.--% | 49.97B | ||
| 32.93x | 6.25x | 22.08x | 0.67% | 41.64B | ||
| 24.04x | 6.35x | 16.42x | 0.96% | 36.8B | ||
| 25.97x | 6.72x | 19.12x | 2.53% | 35.49B | ||
| 16.15x | 1.89x | 10.71x | 0.19% | 33.69B | ||
| Average | 35.92x | 7.18x | 22.36x | 0.76% | 98.4B | |
| Weighted average by Cap. | 44.14x | 8.97x | 26.62x | 0.45% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- BSX Stock
- Valuation Boston Scientific Corporation
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition
















